The ORIGIN trial was funded by Sanofi, who also provided regulatory support, site monitoring and insulin glargine.
| INTRODUCTION
Diabetes is a heterogeneous metabolic disorder with varying degrees of insulin resistance and dysfunction of insulin secretion. Type 1 diabetes typically occurs because of autoimmune damage to the insulinsecreting islet cells, and affected patients often have circulating antibodies directed towards islet cell antigens, most often glutamic acid decarboxylase (anti-glutamic acid dehydrogenase [GAD] antibodies).
Type 2 diabetes is not a result of autoimmunity; however, a subset of subjects with phenotypical type 2 diabetes have anti-GAD antibodies in their serum. Compared with seronegative individuals, those with anti-GAD antibodies have more pronounced beta cell dysfunction and less insulin resistance. 1 Limited data suggest that cardiovascular comorbidity and mortality in such individuals are comparable to that of other people with type 2 diabetes. [2] [3] [4] [5] [6] However, the effect of different treatment regimens on clinical outcomes in the subgroup that are anti-GAD positive remains poorly studied.
The Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial allocated 12 537 participants with either prediabetes or diabetes to receive either titrated basal insulin glargine targeting a normal fasting plasma glucose ≤5.3 mmol/L or standard care; 12 536 of these individuals were also allocated to either 1 g of ethyl esters of n-3 fatty acids or placebo.
A subset of 8162 of the participants had serum levels of anti-GAD measured at baseline. Here, we report cardiovascular, microvascular and glycaemic outcomes in anti-GAD positive and negative subjects.
| MATERIALS AND METHODS
The detailed design of the ORIGIN trial and the main results have been published previously. [7] [8] [9] [10] [11] Episodes of hypoglycaemia confirmed by a self-measured glucose level of ≤3.0 mmol/L were prospectively recorded. All participants gave written informed consent, and a subset also provided consent for the storage and subsequent analyses of blood samples drawn at the time of randomization.
ORIGIN was designed and conducted by an international steering committee of academic investigators led by Prof. Hertzel C. Gerstein.
It was funded by Sanofi, which also provided regulatory support, site monitoring and insulin glargine (Lantus). Pronova BioPharma Norge AS supplied the n-3 fatty acid supplements (Omacor) and placebo.
The study was approved by the ethics committee at each centre, and all participants gave written informed consent. Eligible participants were randomized to the two interventions using a 2 × 2 factorial design and then seen at the study centre after 0.5, 1, 2 and 4 months, and thereafter every 4 months until the study ended after a median (interquartile range) follow-up of 6.2 (5.8-6.8) years.
| Outcomes
The two co-primary outcomes were (a) a composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke, and (b) a composite of any of these events, a revascularization procedure, or hospitalization for heart failure. Non-severe hypoglycaemic episodes since the previous visit were recorded at each visit and patients with HbA1c levels ≤6% (42 mmol/mol) at the end of the study were also considered. 
| Laboratory methods

| Statistical analyses
All statistical analyses were performed using SAS 9.4 for UNIX (SAS Institute Inc., Cary, North Carolina). The effect of each intervention on outcomes was analysed using Cox regression models stratified according to the factorial allocation, baseline diabetes status and prior cardiovascular event. 8 Whether the effect of the intervention differed according to anti-GAD antibody positivity was assessed by including the anti-GAD status in the Cox model as well as an interaction term between the status and treatment allocation.
The relationship between anti-GAD status and an achieved fasting plasma glucose of ≤5.3 mmol/L after 2 years of treatment was analysed using logistic regression with adjustment for age, sex and the variables with P-values (P) < 0.1 in the univariate analysis. Finally, the effect of antibody positivity on the dose of insulin required to achieve normal glycaemia at 2 years in the subgroup of participants who were allocated to insulin glargine was evaluated using a similar approach with linear regression. The nominal level of significance for all the analyses was P < 0.05.
For participants without diabetes at baseline, the effect of the glargine on the development of new diabetes in anti-GAD positive and negative individuals was assessed using a Cochran-Mantel-Haenszel (CMH) test stratified by factorial allocation and adjusted for a history of a prior cardiovascular event. For consistency, the odds ratios (OR) with 95% CI were calculated based on the CMH test, but the interaction between allocation to glargine and both the n-3 fatty acid allocation and the anti-GAD status was assessed using generalized linear models.
| RESULTS
The mean (SD) age of the 8162 participants included in this study was 63.7 (8.0) years; 33.8% were female, and 81.5% had prior diabetes (Table 1 ). The mean levels of blood pressure and lipids at baseline did not differ between anti-GAD positive and negative participants ( Table 1 ). The use of angiotensin-converting enzyme (ACE) inhibitors/angiotensin 2-receptor blockers (ARBs) was higher among anti-GAD positive participants. The participants included in this substudy of the ORIGIN trial did not differ substantially in baseline characteristics compared with those not included (Tables S1 and S2 , Supporting Information).
Compared with 7895 anti-GAD negative participants, the 267 anti-GAD positive participants had a higher prevalence of diagnosed diabetes at baseline (86.5% vs. 81.3%, P = 0.031) and more thyroid disease (10.9% vs. 7.4%, P = 0.034).
3.1 | Cardiovascular and microvascular outcomes overall, and according to glargine and n-3 fatty acid allocation
The overall incidence of the first co-primary outcome did not differ significantly between anti-GAD positive and negative patients (3.06/100 patient-years vs. 2.92/100 patient-years (Table 2) . Nor did the incidence of this outcome differ between anti-GAD positive participants randomized to insulin glargine or to standard glucoselowering treatment, with a HR (95% confidence interval) 0.80 (0.44-1.44) ( Table 2 ), or to n-3 fatty acids or placebo with a HR 0.98 (0.54-1.78) (Table S3) . Furthermore, the incidence of the second coprimary outcome or all-cause death did not differ between anti-GAD positive and negative individuals, neither between anti-GAD positive participants randomized to insulin glargine or to standard treatment, nor to participants randomized to n-3 fatty acids or placebo (Tables 2   and S3 , Supporting Information). 
| Effects on glycaemic control
The incidence of achieving HbA1c ≤ 6.0% (42 mmol/mol) at the end of the study did not differ between anti-GAD positive individuals randomized to insulin glargine or standard care ( Table 2 ).
The number of non-severe, symptomatic hypoglycaemic episodes was not different between anti-GAD positive or negative participants (7.20 vs. 5.99/100 patient-years).
Between randomization and approximately 1 month after all study interventions were stopped at the end of the trial (when an oral glucose tolerance test was administered to people not diagnosed with diabetes by that time), both anti-GAD positive and negative participants who had been allocated to insulin glargine had a lower incidence of diabetes compared with controls (24.5% vs. 31.6%, P = 0.014) with no difference between groups (P for interaction = 0.16). This effect was attenuated when tested approximately 2 months later (Supporting Information Table S4 , data not shown).
| DISCUSSION
The distinction between type 1 and type 2 diabetes has usually been based upon age of onset, the severity of beta cell failure and insulin resistance, and the presence of diabetes-associated auto-antibodies.
Notably, in the present study we observed no differences in duration of diabetes, age at diagnosis or ethnic distribution between anti-GAD negative and positive individuals, but more anti-GAD positive participants had diabetes at inclusion.
The major findings in the present study were that the overall incidence of cardiovascular outcomes was similar in anti-GAD positive and negative patients, and that the incidence of major cardiovascular events did not differ between anti-GAD positive participants randomized to insulin glargine or standard glucose-lowering treatment, or to n-3 fatty acids or placebo.
We confirm the results from previously published observational studies that report at least as high rates of cardiovascular endpoints and mortality in anti-GAD positive individuals as in the typical form of anti-GAD negative patients with phenotypically type 2 diabetes.
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This may be a reminder of the importance of hyperglycaemia per se as a risk factor for cardiovascular disease (CVD).
As previously reported from the full ORIGIN cohort, we found a reduced incidence of new diabetes in the group treated with insulin glargine when an oral glucose tolerance test (OGTT) was performed 1 month after stopping treatment in subjects without diabetes at baseline. The effect was found in both anti-GAD positive and negative individuals. The mean fasting levels of C-peptide at baseline did not differ significantly between the groups, indicating the participants with signs of autoimmune diabetes still had significant endogenous insulin secretion.
The prevalence of anti-GAD antibodies in our cohort was 3.2%
and lower than in many previously reported studies, where numbers Abbreviation: py, patient-years. *P is the P-value for the interaction of glargine allocation and anti-GAD status. The first co-primary was a composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke, and the second co-primary was a composite of any of these events, a revascularization procedure, or hospitalization for heart failure.
usually range from 5% to 14%. 3, [13] [14] [15] This may partly be because of the selection of study participants in ORIGIN. Participants were recruited globally, were aged ≥50 years with vascular disease, were required to be insulin-naïve and had short duration of diabetes or only prediabetes at baseline. This probably resulted in a selected group of anti-GAD positive participants that may differ from an unselected group in a population-based sample.
The strengths of the present study include the randomized controlled design testing relevant therapeutic options over a long follow-up period. Possible weaknesses are (a) its post-hoc nature; (b) the low number of anti-GAD positive participants, and therefore wide confidence intervals to our effect estimates and limited power to detect effects of interventions in anti-GAD positive subjects; and (c) the aforementioned possible selection bias. We also chose to measure only anti-GAD among several autoantibodies known to be associated with autoimmune diabetes. Furthermore, we cannot exclude that the findings may be different in subgroups of patients, i.e. with high or low levels of C-peptide or low anti-GAD titers. Because of the limited number of anti-GAD positive individuals in our study, this could not be explored further.
In conclusion, we report that anti-GAD positive participants included in the ORIGIN study had a similar incidence of cardiovascular outcomes as anti-GAD negative subjects, and that early insulin treatment had a neutral effect compared with standard antihyperglycaemic treatment on important outcomes in anti-GAD positive individuals. 
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